| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5583122 | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Dec, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5583122 | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Dec, 2013
(10 years ago) | |
|
US5583122 (Pediatric) | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Jun, 2014
(9 years ago) | |
| US6165513 | APIL | Film-coated tablet for improved upper gastrointestinal tract safety |
Jun, 2018
(5 years ago) | |
| US6015801 | APIL | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US5994329 | APIL | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6432932 | APIL | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6465443 | APIL | Method for inhibiting bone resorption |
Aug, 2018
(5 years ago) | |
|
US6165513 (Pediatric) | APIL | Film-coated tablet for improved upper gastrointestinal tract safety |
Dec, 2018
(5 years ago) | |
|
US6432932 (Pediatric) | APIL | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US5994329 (Pediatric) | APIL | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6015801 (Pediatric) | APIL | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6465443 (Pediatric) | APIL | Method for inhibiting bone resorption |
Feb, 2019
(5 years ago) | |
| US7718634 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(11 months ago) | |
| US7192938 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(11 months ago) | |
|
US7718634 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(5 months ago) | |
|
US7192938 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(5 months ago) | |
Actonel is owned by Apil.
Actonel contains Risedronate Sodium.
Actonel has a total of 17 drug patents out of which 17 drug patents have expired.
Expired drug patents of Actonel are:
- US5583122
- US5583122*PED
- US6165513
- US6015801
- US5994329
- US6432932
- US6465443
- US6165513*PED
- US6432932*PED
- US5994329*PED
- US6015801*PED
- US6465443*PED
- US7718634
- US7192938
- US7718634*PED
- US7192938*PED
- US5583122
Actonel was authorised for market use on 14 April, 2000.
Actonel is available in tablet;oral dosage forms.
Actonel can be used as method of treating paget's disease using actonel, prevention and treatment of osteoporosis, 35 mg orally once a week for prevention of osteoporosis in postmenopausal women; 35 mg orally once a week for treatment of osteoporosis in postmenopausal women, treatment of osteoporosis in postmenopausal women.
The generics of Actonel are possible to be released after 06 November, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 23, 2012 |
| Pediatric Exclusivity(PED) | Jan 23, 2013 |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 14 April, 2000
Treatment: Method of treating paget's disease using actonel; Prevention and treatment of osteoporosis; 35 mg orally once a week for prevention of osteoporosis in postmenopausal women; 35 mg orally once a week fo...
Dosage: TABLET;ORAL
ACTONEL family patents
